海外の治験の状況「%E8%84%B3%E5%8D%92%E4%B8%AD」での検索結果
334件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 国名
- 登録日
Authorised
- A phase IIIb/IV randomised, controlled study evaluating an intensification treatment strategy of adding enfuvirtide (ENF) to an oral Highly Active AntiRetroviral Therapy (HAART) in treatment experienced patients. - INTENSE Study
- HIV Infection Classification code 10020161
- Germany, Italy, Spain
- 2006-04-25
Authorised
- An open label study of Zonegran (zonisamide) in patients with partial onset seizures.
- Indicated as adjunctive therapy in the treatment of adult patients with partial seizures, with or without secondary generalisation. MedDRA version: 8.0 Level: pt Classification code 10061334
- Denmark, Finland, Germany, Italy, Sweden, United Kingdom
- 2005-08-02
Authorised
- Clinical role of PPAR gamma activator (pioglitazone) in reducing the gastric phlogosis in patiens with istological gastritis.
- Treatment of patients with gastric phlogosis (infected by Helicobacter pylori) MedDRA version: 9.1 Level: LLT Classification code 10017904 Term: Gastroenteritis helicobacter
- Italy
- 2005-11-08
Authorised
- A topical gel for the treatment of atopic eczema
- The medical condition to be investigated in this study is atopic eczema, also known as atopic dermatitis. MedDRA version: 14.1 Level: LLT Classification code 10003641 Term: Atopic eczema System Organ Class: 100000004858 ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
- United Kingdom
- 2013-04-30
Authorised
- Prevention of the return of nephrotic syndrom in children by adding levamisole to the prednison treatment
- steroid sensitive idiopathic nephrotic syndrome MedDRA version: 20.1 Level: PT Classification code 10029164 Term: Nephrotic syndrome System Organ Class: 10038359 - Renal and urinary disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
- Netherlands
- 2017-12-06
Authorised
- Efficacy, Safety, and Pharmacokinetic Profile of ANB020 in Adults with Moderate to Severe Atopic Dermatitis
- Moderate-to-Severe Atopic Dermatitis MedDRA version: 20.0 Level: PT Classification code 10012438 Term: Dermatitis atopic System Organ Class: 10040785 - Skin and subcutaneous tissue disorders ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
- Canada, Czech Republic, Germany, Poland, United Kingdom, United States
- 2018-07-25
Authorised
- A 24 week multinational multi-center study consisting of a 12-week single blind study to evaluate the efficacy and safety of methotrexate versus Azathioprin treatment in adult patients with chronic severe atopic dermatitis (AD) and a 12-week follow up period. - MAcAD
- Patients with severe atopic dermatitis, defined as a score of 8-9 on the Rajka and Langeland criteria who are unresponsive, intolerant or contra-indicated to cyclisporin treatment. MedDRA version: 9.1 Level: LLT Classification code 10003639 Term: Atopic dermatitis
- Netherlands
- 2009-06-03
Authorised
- Multicenter, Prospective, Comparative, Randomized Controlled Clinical investigation on the performance of Promelaxin® micro-enemas versus oral administration of Macrogol 4000, in the treatment of chronic constipation in infants aged between 6 and 24 months.
- Chronic Functional Constipation MedDRA version: 18.1 Level: LLT Classification code 10067374 Term: Stypsis System Organ Class: 100000004865 ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
- Italy
- 2016-04-04
Authorised
- A Safety and Efficacy Study for Alzheimer's Disease (Prodromal AD)
- prodromal Alzheimer's Disease MedDRA version: 16.0 Level: HLT Classification code 10001897 Term: Alzheimer's disease (incl subtypes) System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Argentina, Australia, Austria, Belgium, Brazil, Canada, Czech Republic, Finland, France, Germany, Italy, Japan, Netherlands, New Zealand, Norway, South Africa, Spain, Switzerland, United Kingdom, United States
- 2013-09-17
Authorised
- A one-weel, randomized, double-blind, placebo-controlled pilot trial to evaluate oral R129160 (60 mg b.i.d.) on the alleviation of itch in atopic dermatitis patients - Oral R129160 in atopic dermatitis
- Atopic Dermatitis
- Belgium, Czech Republic
- 2005-08-17